Does intraurethral erythropoietin administration effect wound healing after hypospadias correction? an experimental rat study

Author(s):  
Eda Tokat ◽  
Yildiray Yildiz ◽  
Pinar Eylem Eser ◽  
Muhammet Fatih Kilinc ◽  
Omer Gokhan Doluoglu
Keyword(s):  
2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Metin Çalışır ◽  
Aysun Akpınar ◽  
Ahmet Cemil Talmaç ◽  
Aysan Lektemur Alpan ◽  
Ömer Fahrettin Göze

Introduction. Humic acid was previously shown to enhance cutaneous wound healing and show antibacterial properties; however, it has not been used for wound healing in the oral cavity. Thus, the goal of this study was the evaluation of the effect of the humic acid on the healing of excisional wounds in an experimental rat study. Materials and Methods. A circular wound on mid-palatal surfaces was made on a total of 77 Wistar rats by using a 3-mm biopsy punch under anesthesia. The animals were divided into 4 groups as baseline, saline control (0.09%), chlorhexidine gluconate (0.05%), and humic acid (80 mg/kg) and were treated with these materials for 7 days. Results. The rats were observed for 3 weeks in order to track the wound closure rates. Both humic acid treatment and chlorhexidine gluconate treatment resulted in statistically significant enhanced rate of wound closure compared to the saline control on both the 1st and 2nd weeks of treatment. Humic acid treatment for the wounds in the palate resulted in enhanced recovery compared to not only saline control but also chlorhexidine gluconate treatment. Conclusion. In this study, humic acid was shown to enhance healing of oral wounds for the first time in the literature. These findings indicate that humic acid can be used as an alternative to current treatment methods for oral wounds.


Author(s):  
Rick L. Vaughn ◽  
Shailendra K. Saxena ◽  
John G. Sharp

We have developed an intestinal wound model that includes surgical construction of an ileo-cecal patch to study the complex process of intestinal wound healing. This allows approximation of ileal mucosa to the cecal serosa and facilitates regeneration of ileal mucosa onto the serosal surface of the cecum. The regeneration of ileal mucosa can then be evaluated at different times. The wound model also allows us to determine the rate of intestinal regeneration for a known size of intestinal wound and can be compared in different situations (e.g. with and without EGF and Peyer’s patches).At the light microscopic level it appeared that epithelial cells involved in regeneration of ileal mucosa originated from the enlarged crypts adjacent to the intestinal wound and migrated in an orderly fashion onto the serosal surface of the cecum. The migrating epithelial cells later formed crypts and villi by the process of invagination and evagination respectively. There were also signs of proliferation of smooth muscles underneath the migratory epithelial cells.


2020 ◽  
Vol 134 (16) ◽  
pp. 2189-2201
Author(s):  
Jessica P.E. Davis ◽  
Stephen H. Caldwell

Abstract Fibrosis results from a disordered wound healing response within the liver with activated hepatic stellate cells laying down dense, collagen-rich extracellular matrix that eventually restricts liver hepatic synthetic function and causes increased sinusoidal resistance. The end result of progressive fibrosis, cirrhosis, is associated with significant morbidity and mortality as well as tremendous economic burden. Fibrosis can be conceptualized as an aberrant wound healing response analogous to a chronic ankle sprain that is driven by chronic liver injury commonly over decades. Two unique aspects of hepatic fibrosis – the chronic nature of insult required and the liver’s unique ability to regenerate – give an opportunity for pharmacologic intervention to stop or slow the pace of fibrosis in patients early in the course of their liver disease. Two potential biologic mechanisms link together hemostasis and fibrosis: focal parenchymal extinction and direct stellate cell activation by thrombin and Factor Xa. Available translational research further supports the role of thrombosis in fibrosis. In this review, we will summarize what is known about the convergence of hemostatic changes and hepatic fibrosis in chronic liver disease and present current preclinical and clinical data exploring the relationship between the two. We will also present clinical trial data that underscores the potential use of anticoagulant therapy as an antifibrotic factor in liver disease.


Sign in / Sign up

Export Citation Format

Share Document